D. Sheng

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

J. Chan, M. Davies, K. Kaufman, 2008, Diabetes, obesity & metabolism.

Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

M. Nauck, G. Meininger, P. Stein, 2007, Diabetes, obesity & metabolism.

Original article Sitagliptin 100mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement

N. Thornberry, G. Herman, D. Williams-Herman, 2009 .

Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement

N. Thornberry, B. Goldstein, K. Kaufman, 2009, Current medical research and opinion.

Melatonin reverses type 2 diabetes-induced cognitive deficits via attenuation of oxidative/nitrosative stress and NF-κB-mediated neuroinflammation in rat hippocampus

Zhongfu Wang, Yeo Jing Ping, D. Sheng, 2018 .

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study

M. Davies, M. Nauck, K. Kaufman, 2010, International journal of clinical practice.